Cellectis (NASDAQ:CLLS) Trading 7% Higher

Cellectis SA (NASDAQ:CLLS)’s share price traded up 7% on Tuesday . The stock traded as high as $11.30 and last traded at $11.13, 133,926 shares changed hands during trading. An increase of 9% from the average session volume of 122,943 shares. The stock had previously closed at $10.40.

Several research analysts have recently weighed in on the stock. BTIG Research assumed coverage on shares of Cellectis in a research note on Friday, August 9th. They set a “buy” rating and a $37.00 price target on the stock. BidaskClub downgraded shares of Cellectis from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 17th. Goldman Sachs Group set a $20.00 price objective on shares of Cellectis and gave the company a “hold” rating in a research report on Monday, August 12th. Zacks Investment Research upgraded shares of Cellectis from a “sell” rating to a “hold” rating in a research report on Monday, August 26th. Finally, ValuEngine upgraded shares of Cellectis from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. Cellectis has an average rating of “Hold” and an average price target of $31.67.

The stock has a market capitalization of $441.48 million, a P/E ratio of -5.77 and a beta of 1.77. The company’s 50-day moving average price is $11.99 and its 200 day moving average price is $15.87. The company has a debt-to-equity ratio of 0.11, a quick ratio of 8.46 and a current ratio of 8.47.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.79) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.18). The firm had revenue of $2.93 million for the quarter, compared to the consensus estimate of $3.45 million. Cellectis had a negative net margin of 813.06% and a negative return on equity of 21.51%. Analysts predict that Cellectis SA will post -2.9 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the company. Cubist Systematic Strategies LLC bought a new stake in shares of Cellectis during the 2nd quarter valued at $103,000. Aperio Group LLC bought a new stake in Cellectis in the 2nd quarter valued at $147,000. A.R.T. Advisors LLC bought a new stake in Cellectis in the 2nd quarter valued at $171,000. OneAscent Financial Services LLC bought a new stake in Cellectis in the 2nd quarter valued at $257,000. Finally, D. E. Shaw & Co. Inc. bought a new stake in Cellectis in the 2nd quarter valued at $502,000. Hedge funds and other institutional investors own 31.65% of the company’s stock.

Cellectis Company Profile (NASDAQ:CLLS)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

Read More: Purposes and Functions of the Federal Reserve

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.